[
  {
    "ts": null,
    "headline": "ReAlta Life Sciences Secures European Orphan Drug Status for Graft-vs-Host Disease Treatment",
    "summary": "By Karen Roman ReAlta Life Sciences, Inc. said it was granted Orphan Drug Designation by the European Medicines Agency (EMA) for RLS-0071 (pegtarazimod), to treat Graft-versus-Host Disease (GvHD). The designation was supported by preliminary data from the company’s Phase 2 trial and follows FDA Orphan Drug and Fast Track designations received in 2024, it stated. “Receiving […]",
    "url": "https://finnhub.io/api/news?id=703f5db1650c9f683fc96d61677c0bf9c113f0520340000185097b1de14c6937",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755816926,
      "headline": "ReAlta Life Sciences Secures European Orphan Drug Status for Graft-vs-Host Disease Treatment",
      "id": 136472415,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "By Karen Roman ReAlta Life Sciences, Inc. said it was granted Orphan Drug Designation by the European Medicines Agency (EMA) for RLS-0071 (pegtarazimod), to treat Graft-versus-Host Disease (GvHD). The designation was supported by preliminary data from the company’s Phase 2 trial and follows FDA Orphan Drug and Fast Track designations received in 2024, it stated. “Receiving […]",
      "url": "https://finnhub.io/api/news?id=703f5db1650c9f683fc96d61677c0bf9c113f0520340000185097b1de14c6937"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Biologics and Biosimilars Market size & share revenue was valued at approximately USD 478.83 Billion in 2024 and is expected to reach USD 527.36 Billion in 2025 and is expected to reach around USD 1,320.19 Billion by 2034, at a CAGR of 10.42% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen Inc., P",
    "url": "https://finnhub.io/api/news?id=9aaef2be70e1f2d712f1b47c8b1dce64987548f13e4fff641e2d6a7b53569d78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755793800,
      "headline": "[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 136467561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Biologics and Biosimilars Market size & share revenue was valued at approximately USD 478.83 Billion in 2024 and is expected to reach USD 527.36 Billion in 2025 and is expected to reach around USD 1,320.19 Billion by 2034, at a CAGR of 10.42% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen Inc., P",
      "url": "https://finnhub.io/api/news?id=9aaef2be70e1f2d712f1b47c8b1dce64987548f13e4fff641e2d6a7b53569d78"
    }
  },
  {
    "ts": null,
    "headline": "Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?",
    "summary": "J&J battles Stelara losses, talc lawsuits, tariffs and China headwinds while banking on growth plans and new launches to stay resilient.",
    "url": "https://finnhub.io/api/news?id=70167be1e6cf3fe79fb67c7dc44e2fff75d33431d09ba3d2b7bd4f75b20f772b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755782280,
      "headline": "Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?",
      "id": 136467596,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "J&J battles Stelara losses, talc lawsuits, tariffs and China headwinds while banking on growth plans and new launches to stay resilient.",
      "url": "https://finnhub.io/api/news?id=70167be1e6cf3fe79fb67c7dc44e2fff75d33431d09ba3d2b7bd4f75b20f772b"
    }
  },
  {
    "ts": null,
    "headline": "SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM",
    "summary": "Singzyme, a Singapore-based biotech startup pioneering next-generation bioconjugation solutions, has been named the winner of the 2025 Golden Ticket Programme in Singapore. The award is part of a joint programme by Amgen, a U.S.-based leader in biologic medicines and NSG BioLabs, Singapore's leading provider of biotechnology co-working laboratories and offices.",
    "url": "https://finnhub.io/api/news?id=5c2320ddc23a6eb95a602d2daf9ce018c12bbdd8db0541c66d8ac910445e4d3b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755769080,
      "headline": "SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM",
      "id": 136452285,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Singzyme, a Singapore-based biotech startup pioneering next-generation bioconjugation solutions, has been named the winner of the 2025 Golden Ticket Programme in Singapore. The award is part of a joint programme by Amgen, a U.S.-based leader in biologic medicines and NSG BioLabs, Singapore's leading provider of biotechnology co-working laboratories and offices.",
      "url": "https://finnhub.io/api/news?id=5c2320ddc23a6eb95a602d2daf9ce018c12bbdd8db0541c66d8ac910445e4d3b"
    }
  }
]